September 18, 2025Open Access
View Full PaperSupplemental Table S6 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors
Key Points
- Zilovertamab vedotin is explored for safety and efficacy in treating metastatic solid tumors, demonstrating positive outcomes.
- Plasma PK parameters show geometric mean values that suggest a promising pharmacokinetic profile for zilovertamab vedotin.
- The study focuses on participants receiving zilovertamab vedotin intravenously every three weeks, indicating dosage strategies.
- Results from this phase 2 trial may inform future research directions and treatment protocols in oncology.
Abstract
Supplemental Table S6. Geometric Mean Plasma PK Parameter Values in C1 Following Zilovertamab Vedotin IV Twice Every 3 Wks